BioSpace News Archive

MacroGenics, Inc. announced that its 2020 Annual Meeting of Stockholders will now be held by means of a virtual format only due to the public health and safety concerns related to the novel coronavirus pandemic and related recommendations and orders from federal and state governmental authorities.

Myriad Genetics, Inc., a leader in molecular diagnostics and precision medicine, announced that it will hold its fiscal third-quarter 2020 sales and earnings conference call with investors and analysts at 4:30 p.m. EDT on Tuesday, May 5, 2020.

DexCom, Inc. reported its financial results as of and for the quarter ended March 31, 2020.

Dynavax Technologies Corporation, a biopharmaceutical company focused on developing and commercializing novel vaccines, reported immunogenicity and safety data from an interim analysis of the ongoing clinical trial evaluating HEPLISAV-B® [Hepatitis B Vaccine, Adjuvanted] in patients undergoing hemodialysis.

Cerner Corporation announced results for the 2020 first quarter that ended March 31, 2020.

Health Catalyst, Inc., a leading provider of data and analytics technology and services to healthcare organizations, will release its 2020 first quarter operating results on Tuesday, May 12, 2020, after market close.

Revenue of $230.9 million in the first quarter of 2020 increased 15.0% from revenue of $200.7 million for the comparable prior-year period, representing a backlog conversion rate of 18.0%.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for patent applications covering the formulation of the 72 mcg dose of LINZESS® (linaclotide) and methods of using the formulation

Masimo (Nasdaq: MASI) today announced its financial results for the first quarter ended March 28, 2020.

Senseonics Holdings, Inc. (NYSE American: SENS) a medical technology company focused on the development and commercialization of the first and only long-term, implantable continuous glucose monitoring (CGM) system for people with diabetes, announced regulatory approval that the Eversense® XL Sensor is no longer contraindicated for MRI which means that the sensor does NOT need to be removed from under the skin during MRI scanning.